Skip to content
Screener

Capricor Therapeutics CAPR Business Segments — Nonoperating Income Expense

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Nonoperating Income Expense
$5.36M+109%
LQD
LQDASingle Reportable — Nonoperating Income Expense
-$4.72M-60.5%
Merit Medical Systems logo
MMSISingle Reportable — Nonoperating Income Expense
$9.39M+405%
Pulse Biosciences, Inc. logo
PLSESingle Reportable — Nonoperating Income Expense
-$615K+44.4%
Aclaris Therapeutics logo
ACRSSingle Reportable — Nonoperating Income Expense
$2.73M-8.3%
Axcelis Technologies logo
ACLSSingle Reportable — Nonoperating Income Expense
$5.07M-16.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$242.07M-31.6%
Enterprise value$151.43M-54.3%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Total revenueThree months ended March 31, 2026 / —Three months ended March 31, 2025 / —
Total general and administrative expense9,395,9416,067,376
Operating loss(36,772,853)(24,982,948)
Investment income2,904,506729,542
Other income (expense)(72,998)(138,188)
Total non-operating income, net2,831,508591,354
Loss before income taxes(33,941,345)(24,391,594)
(Provision for) benefit from income taxes
Net loss$(33,941,345)$(24,391,594)

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's business segments — nonoperating income expense?
Capricor Therapeutics (CAPR) reported business segments — nonoperating income expense of $2.83M in Q1 2026.
How has Capricor Therapeutics's business segments — nonoperating income expense changed year-over-year?
Capricor Therapeutics's business segments — nonoperating income expense increased by 378.8% year-over-year, from $591.35K to $2.83M.
What does business segments — nonoperating income expense mean?
This represents the net total of all financial activities not directly related to the company's primary biotechnology research and commercial operations. It aggregates interest income, interest expenses, and other non-core financial items. This metric is essential for understanding the company's total financial health beyond its R&D performance.

Ask your AI about Capricor Therapeutics's business segments — nonoperating income expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude